Financial Performance - The company's revenue for Q1 2025 was CNY 196,499,491.35, representing a 7.10% increase compared to CNY 183,475,935.51 in the same period last year[5] - Net profit attributable to shareholders reached CNY 16,305,126.89, a significant increase of 93.56% from CNY 8,423,929.99 in the previous year[5] - Basic earnings per share rose to CNY 0.1635, up 97.46% from CNY 0.0828 in the previous year[5] - Operating profit for the current period was ¥18,195,945.08, up 73.5% from ¥10,492,562.26 in the previous period[17] - Net profit for the current period was ¥16,305,126.89, representing a 93.5% increase from ¥8,423,929.99 in the previous period[17] Cash Flow - The net cash flow from operating activities was CNY 24,678,125.49, showing a remarkable increase of 306.77% compared to CNY 6,066,863.78 in the same period last year[5] - Cash and cash equivalents at the end of the period totaled ¥293,098,750.80, compared to ¥220,687,086.13 at the end of the previous period[21] - The cash and cash equivalents net increase was CNY 3,874,961.25, a 125.61% improvement compared to a decrease of CNY 15,129,696.08 in the previous year[9] - The company reported a net cash outflow from investing activities of ¥19,974,405.55, worsening from a net outflow of ¥13,052,195.35 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,496,270,124.07, a slight decrease of 0.55% from CNY 1,504,528,918.05 at the end of the previous year[5] - Total liabilities decreased to ¥419,765,155.50 from ¥446,857,834.56, a reduction of about 6.07%[16] - The company's equity attributable to shareholders increased to CNY 1,076,504,968.57, reflecting a growth of 1.78% from CNY 1,057,671,083.49 at the end of the previous year[5] - Current assets totaled ¥942,025,659.66, down from ¥952,037,157.23, indicating a decline of approximately 1.26%[15] Inventory and Receivables - Accounts receivable rose to ¥129,280,731.92 from ¥120,242,245.29, marking an increase of approximately 7.93%[15] - The company’s inventory increased slightly from ¥115,551,553.67 to ¥116,623,924.61, reflecting a growth of approximately 0.93%[15] - The company reported a decrease in accounts payable from ¥49,493,170.61 to ¥47,766,193.03, a decline of about 3.49%[16] Investment Activities - The company experienced a 53.03% increase in cash flow from investing activities, amounting to CNY -19,974,405.55, primarily due to increased purchases of financial products[9] - The company’s long-term investments remained stable at ¥374,400.42[15] Accounting Standards - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[22]
恩威医药(301331) - 2025 Q1 - 季度财报